Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126685 | 0.86 | DHFR (1.00) | DHFR | |
| SCHEMBL1154447 | 0.86 | DHFR (1.00) | DHFR | |
| SCHEMBL1155253 | 0.84 | DHFR (0.75) | DHFR | |
| SCHEMBL4320937 | 0.83 | DHFR (1.00) | DHFR | |
| SCHEMBL18314388 | 0.81 | DHFR (0.68) | DHFR | |
| SCHEMBL4316405 | 0.79 | DHFR (1.00) | DHFR | |
| SCHEMBL2127633 | 0.77 | DHFR (0.63) | DHFR | |
| SCHEMBL1994777 | 0.77 | TYMS (1.00) | DHFR | |
| SCHEMBL18305876 | 0.74 | DHFR (0.58) | DHFR | |
| SCHEMBL18314395 | 0.74 | DHFR (0.58) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099806-A1 | METHOD FOR THE DETECTION OF SCUTICOCILIATE PARASITES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-06-08 | — | — | WO | claimed |
| EP-4616196-A1 | METHOD FOR DIFFERENTIATING ASFV INFECTED FROM ASFV VACCINATED ANIMALS | Gold Standard Diagnostics Madrid, S.A. (ES) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024110453-A1 | METHOD FOR DIFFERENTIATING ASFV INFECTED FROM ASFV VACCINATED ANIMALS | GOLD STANDARD DIAGNOSTICS MADRID, S.A. (ES) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024061978-A1 | METHOD FOR THE DIAGNOSIS OF ULCERATIVE COLITIS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2024-03-28 | — | — | WO | disclosed |
| EP-4343001-A1 | METHOD FOR THE DIAGNOSIS OF ULCERATIVE COLITIS | Universidade de Santiago de Compostela (ES) | 2024-03-27 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023099806-A1 | METHOD FOR THE DETECTION OF SCUTICOCILIATE PARASITES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-06-08 | — | — | WO | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | DHFR 420/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | DHFR 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.